PSTV Plus Therapeutics
- 1.0900
- +0.1000+10.10%
- 1.0500
- -0.0400-3.67%
Plus Therapeutics News
Plus Therapeutics Is Maintained at Buy by Ascendiant Capital
Plus Therapeutics Analyst Ratings
Ascendiant Capital Maintains Buy on Plus Therapeutics, Lowers Price Target to $19
H.C. Wainwright Maintains Plus Therapeutics(PSTV.US) With Buy Rating, Maintains Target Price $8
Maxim Group Maintains Plus Therapeutics(PSTV.US) With Buy Rating, Maintains Target Price $4
Positive Outlook for Plus Therapeutics: Strong Financial Support and Clinical Advancements Justify Buy Rating
Plus Therapeutics Price Target Maintained With a $8.00/Share by HC Wainwright & Co.
Plus Therapeutics Analyst Ratings
H.C. Wainwright Maintains Plus Therapeutics(PSTV.US) With Buy Rating, Maintains Target Price $8
Plus Therapeutics Is Maintained at Buy by Ascendiant Capital
Buy Rating Affirmed for Plus Therapeutics Amid Strong Clinical Results and Positive Financial Outlook
Maxim Group Maintains Plus Therapeutics(PSTV.US) With Buy Rating, Maintains Target Price $4
Buy Rating Affirmed for Plus Therapeutics on Strong Financials and Promising Clinical Trials
Plus Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Plus Therapeutics, Maintains $8 Price Target
Buy Rating Affirmed for Plus Therapeutics Amidst Promising Clinical Trial Results
Buy Rating Affirmed for Plus Therapeutics on Strong Clinical Progress and Robust Financial Health
Plus Therapeutics Inc: Ascendiant Capital Markets cuts target price from $22 to $21
Buy Rating Justified by Plus Therapeutics' Strategic Acquisition and Strong Pipeline Prospects
Analysts' Top Healthcare Picks: OrganiGram Holdings (OGI), Plus Therapeutics (PSTV)
No Data
